1. INTENDED USE
Reagent 20/296 is prepared from X-347A (H3N2) (A/Paris/2554/2019 (H3N2) x A/PR/8/34) which was processed in 250μl volumes as liquid stock. The derivation and known passage history of X-347A (H3N2) is attached.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
No unitage is assigned to this material

4. CONTENTS
Country of origin of biological material: United Kingdom.
Each vial contains 250μl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen’s eggs.

5. STORAGE
Store in the dark at -70°C or below

6. DIRECTIONS FOR OPENING
Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL
Ready to use

8. STABILITY
Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES
NA

10. ACKNOWLEDGEMENTS
NA

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:

http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th>Toxicological properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance:</td>
<td></td>
</tr>
<tr>
<td>Clear liquid</td>
<td>Corrosive: No</td>
</tr>
<tr>
<td>Stable:</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Oxidising: No</td>
</tr>
<tr>
<td>Hygroscopic:</td>
<td>No</td>
</tr>
<tr>
<td>No</td>
<td>Irritant: No</td>
</tr>
<tr>
<td>Flammable:</td>
<td>Handling: See caution, Section 2</td>
</tr>
<tr>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Other (specify):</td>
<td>Live influenza virus</td>
</tr>
</tbody>
</table>

Suggested First Aid
Inhalation: Seek medical advice
Ingestion: Seek medical advice
Contact with eyes: Wash with copious amounts of water. Seek medical advice
Contact with skin: Wash thoroughly with water.

Action on Spillage and Method of Disposal
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.
Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.
Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: 0.25g per vial

Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable. Attached: No

Passage history of X-347A (H3N2)

<table>
<thead>
<tr>
<th>Cumulative number of passages</th>
<th>Passage numbers at each stage</th>
<th>Lot</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1-E4</td>
<td>E4</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>E5-E14</td>
<td>E4/E10</td>
<td>E#6447</td>
<td>NYMC, USA</td>
</tr>
<tr>
<td>E15</td>
<td>E4/E10/E1</td>
<td>45680</td>
<td>NIBSC, UK</td>
</tr>
</tbody>
</table>

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud’s broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus is available at GISAID with the accession number EPI_ISL_883194.
Derivation of NYMC X-347A
A/Paris/2554/2019 (H3N2) with A/PR/8/34
High Yield A H3N2 Reassortant (5:3)
with A/PR/8/34 M, PB2, PA, NS and NP genes and
A/Paris/2554/2019 PB1, HA, and NA genes

Exper. # 4859
A/Paris/2554/2019
H3N2
#201245 E4 (Am2Al2)
GP 128(10^{-5}) 20/2/2020

Passages at New York Medical College

<table>
<thead>
<tr>
<th>Passage No.</th>
<th>Final Titer</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10^{-1}</td>
<td>HA—1:32</td>
</tr>
</tbody>
</table>

A/Paris/2554/2019 (H3N2) x A/PR/8/34

<table>
<thead>
<tr>
<th>Passage No.</th>
<th>Final Titer</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>10^{-1} + 10^{-3}</td>
<td>HA—1:2048, A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab)</td>
</tr>
<tr>
<td>3</td>
<td>10^{-1}</td>
<td>HA—1:1024, A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab)</td>
</tr>
<tr>
<td>4</td>
<td>10^{-1}</td>
<td>HA—1:256, A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab)</td>
</tr>
<tr>
<td>5</td>
<td>10^{-3}</td>
<td>+ A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab)</td>
</tr>
<tr>
<td>6</td>
<td>10^{-4}</td>
<td>HA—128, A/PR/8/34 antisera (as) A/PR/8/34 HANA antibodies (ab)</td>
</tr>
</tbody>
</table>
HA Yield by UPLC Analysis (µg HA/ml allantoic fluid)

<table>
<thead>
<tr>
<th></th>
<th>wt (wild type)</th>
<th>X-347A</th>
<th>Fold Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>10^{-9}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>10^{-9}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>10^{-9}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>10^{-5}</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NYMC X-347A (E4/E10)  
E#6447 NYMC

HA and NA, genes were identified as A/Paris/2554/2019 by RT-PCR/RFLP gene analysis. PA, NS and NP genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis.

The PB1 gene was identified as A/Paris/2554/2019 by qPCR analysis. M and PB2 genes were identified as A/PR/8/34 by qPCR analysis.

SPF eggs were used for all reassortant passages.

Virus seed was shown to be sterile. Sterility testing was performed by streaking the sample on blood agar plates and incubating for 48 hours at 37 °C.